Morrill Haley J, Caffrey Aisling R, Gaitanis Melissa M, LaPlante Kerry L
Veterans Affairs Medical Center, Infectious Diseases Research Program, Providence, Rhode Island, United States of America.
University of Rhode Island, Department of Pharmacy Practice, College of Pharmacy, Kingston, Rhode Island, United States of America.
PLoS One. 2016 Mar 15;11(3):e0150795. doi: 10.1371/journal.pone.0150795. eCollection 2016.
Prospective audit and feedback is a core antimicrobial stewardship program (ASP) strategy; however its impact is difficult to measure.
Our quasi-experimental study measured the effect of an ASP on clinical outcomes, antimicrobial use, resistance, costs, patient safety (adverse drug events [ADE] and Clostridium difficile infection [CDI]), and process metrics pre- (9/10-10/11) and post-ASP (9/12-10/13) using propensity adjusted and matched Cox proportional-hazards regression models and interrupted time series (ITS) methods.
Among our 2,696 patients, median length of stay was 1 day shorter post-ASP (5, interquartile range [IQR] 3-8 vs. 4, IQR 2-7 days, p<0.001). Mortality was similar in both periods. Mean broad-spectrum (-11.3%), fluoroquinolone (-27.0%), and anti-pseudomonal (-15.6%) use decreased significantly (p<0.05). ITS analyses demonstrated a significant increase in monthly carbapenem use post-ASP (trend: +1.5 days of therapy/1,000 patient days [1000PD] per month; 95% CI 0.1-3.0). Total antimicrobial costs decreased 14%. Resistance rates did not change in the one-year post-ASP period. Mean CDI rates/10,000PD were low pre- and post-ASP (14.2 ± 10.4 vs. 13.8 ± 10.0, p = 0.94). Fewer patients experienced ADEs post-ASP (6.0% vs. 4.4%, p = 0.06).
Prospective audit and feedback has the potential to improve antimicrobial use and outcomes, and contain bacterial resistance. Our program demonstrated a trend towards decreased length of stay, broad-spectrum antimicrobial use, antimicrobial costs, and adverse events.
前瞻性审核与反馈是抗菌药物管理计划(ASP)的一项核心策略;然而,其影响难以衡量。
我们的准实验研究使用倾向调整和匹配的Cox比例风险回归模型以及中断时间序列(ITS)方法,在实施ASP之前(9/10 - 10/11)和之后(9/12 - 10/13)测量了ASP对临床结局、抗菌药物使用、耐药性、成本、患者安全(药物不良事件 [ADE] 和艰难梭菌感染 [CDI])以及流程指标的影响。
在我们的2696例患者中,ASP实施后中位住院时间缩短了1天(5天,四分位间距 [IQR] 3 - 8天 对比 4天,IQR 2 - 7天,p<0.001)。两个时期的死亡率相似。平均广谱抗菌药物(-11.3%)、氟喹诺酮类(-27.0%)和抗假单胞菌药物(-15.6%)的使用量显著下降(p<0.05)。ITS分析表明,ASP实施后每月碳青霉烯类药物的使用量显著增加(趋势:每月增加1.5天治疗量/1000患者日 [1000PD];95%置信区间0.1 - 3.0)。抗菌药物总成本下降了14%。ASP实施后的一年中耐药率没有变化。ASP实施前后每10000PD的平均CDI发生率较低(14.2 ± 10.4对比13.8 ± 10.0,p = 0.94)。ASP实施后经历ADE的患者较少(6.0%对比4.4%,p = 0.06)。
前瞻性审核与反馈有可能改善抗菌药物的使用和结局,并控制细菌耐药性。我们的计划显示出住院时间、广谱抗菌药物使用、抗菌药物成本和不良事件有下降的趋势。